Distinct roles of HMGB1 in the regulation of P‑glycoprotein expression in the liver and kidney of mice with lipopolysaccharide‑induced inflammation

Kawase,Atsushi; Irie,Kota; Matsuda,Naoya; Takai,Yuzuki; Shimada,Hiroaki; Iwaki,Masahiro

doi:10.3892/mmr.2022.12858

Distinct roles of HMGB1 in the regulation of P‑glycoprotein expression in the liver and kidney of mice with lipopolysaccharide‑induced inflammation

Authors:
- Atsushi Kawase
- Kota Irie
- Naoya Matsuda
- Yuzuki Takai
- Hiroaki Shimada
- Masahiro Iwaki
View Affiliations

Affiliations: Department of Pharmacy, Faculty of Pharmacy, Kindai University, Higashiosaka, Osaka 577‑8502, Japan
Published online on: September 21, 2022 https://doi.org/10.3892/mmr.2022.12858
Article Number: 342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of high mobility group box 1 (HMGB1) in the regulation of efflux transporters in the liver and kidney remains unclear, although it has been reported that HMGB1 can increase P‑glycoprotein (P‑gp) expression in the brain. The present study aimed to clarify the involvement of HMGB1 in the regulation of P‑gp expression in the liver and kidney of mice with lipopolysaccharide (LPS)‑induced inflammation. Mice were treated with LPS or LPS + glycyrrhizin (GL); GL is as an HMGB1 inhibitor. Subsequently, the expression levels of transporters, such as P‑gp, and HMGB1 receptors, such as toll‑like receptor (TLR)4 and receptor for advanced glycation end‑products (RAGE), were determined by quantitative PCR and LC‑MS/MS‑based targeted proteomics. For the in vitro study, HepG2 and KMRC‑1 cells were used, as was a co‑culture of KMRC‑1 and differentiated THP‑1 cells. The mRNA and protein expression levels of Mdr1a and Tlr4 in the kidneys of LPS + GL‑treated mice were significantly decreased compared with those in LPS mice. The results indicated that HMGB1 had little effect on the expression of Mdr1a and Tlr4 in the liver, since there was little change in of Mdr1a and Mdr1b expression between the LPS and LPS + GL‑treated mice. Notably, regarding MDR1 mRNA expression, KMRC‑1 cells were more responsive to LPS than HepG2 cells, and KMRC‑1 cells treated with LPS exhibited increased levels compared with control KMRC‑1 cells. In differentiated THP‑1 cells, LPS treatment decreased the mRNA expression levels of TLR4, whereas they were restored to control levels by HMGB1. In conclusion, HMGB1 in the plasma and TLR4 in macrophages may be involved in the regulation of P‑gp expression in the kidneys of inflamed mice.

View Figures

View References

1	Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL and Müller M: Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down–regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology. 28:1637–1644. 1998. View Article : Google Scholar : PubMed/NCBI
2	Hartmann G, Vassileva V and Piquette-Miller M: Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos. 33:820–828. 2005. View Article : Google Scholar : PubMed/NCBI
3	Kawase A, Nakasaka M, Bando H, Yasuda S, Shimada H and Iwaki M: Changes in radixin expression and interaction with efflux transporters in the liver of adjuvant-induced arthritic rats. Inflammation. 43:85–94. 2020. View Article : Google Scholar : PubMed/NCBI
4	Kawase A, Norikane S, Okada A, Adachi M, Kato Y and Iwaki M: Distinct alterations in ATP-binding cassette transporter expression in liver, kidney, small intestine, and brain in adjuvant-induced arthritic rats. J Pharm Sci. 103:2556–2564. 2014. View Article : Google Scholar : PubMed/NCBI
5	Rouhiainen A, Kuja-Panula J, Wilkman E, Pakkanen J, Stenfors J, Tuominen RK, Lepäntalo M, Carpén O, Parkkinen J and Rauvala H: Regulation of monocyte migration by amphoterin (HMGB1). Blood. 104:1174–1182. 2004. View Article : Google Scholar : PubMed/NCBI
6	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
7	Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ and Yang H: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 26:174–179. 2006. View Article : Google Scholar : PubMed/NCBI
8	Hreggvidsdóttir HS, Lundberg AM, Aveberger AC, Klevenvall L, Andersson U and Harris HE: High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med. 18:224–230. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhang C, Dong H, Chen F, Wang Y, Ma J and Wang G: The HMGB1-RAGE/TLR-TNF-α signaling pathway may contribute to kidney injury induced by hypoxia. Exp Ther Med. 17:17–26. 2019.PubMed/NCBI
10	Godowski PJ: A smooth operator for LPS responses. Nat Immunol. 6:544–546. 2005. View Article : Google Scholar : PubMed/NCBI
11	Zhong H, Li X, Zhou S, Jiang P, Liu X, Ouyang M, Nie Y, Chen X, Zhang L, Liu Y, et al: Interplay between RAGE and TLR4 regulates HMGB1-induced inflammation by promoting cell surface expression of RAGE and TLR4. J Immunol. 205:767–775. 2020. View Article : Google Scholar : PubMed/NCBI
12	Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A and Abraham E: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 279:7370–7377. 2004. View Article : Google Scholar : PubMed/NCBI
13	Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol. 5:331–342. 2005. View Article : Google Scholar : PubMed/NCBI
14	Chen GY, Tang J, Zheng P and Liu Y: CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 323:1722–1725. 2009. View Article : Google Scholar : PubMed/NCBI
15	Chen Y, Huang XJ, Yu N, Xie Y, Zhang K, Wen F, Liu H and Di Q: HMGB1 contributes to the expression of P-glycoprotein in mouse epileptic brain through toll-like receptor 4 and receptor for advanced glycation end products. PLoS One. 10:e01409182015. View Article : Google Scholar : PubMed/NCBI
16	Xie Y, Yu N, Chen Y, Zhang K, Ma HY and Di Q: HMGB1 regulates P-glycoprotein expression in status epilepticus rat brains via the RAGE/NF-κB signaling pathway. Mol Med Rep. 16:1691–1700. 2017. View Article : Google Scholar : PubMed/NCBI
17	Wang F, Ji S, Wang M, Liu L, Li Q, Jiang F, Cen J and Ji B: HMGB1 promoted P-glycoprotein at the blood-brain barrier in MCAO rats via TLR4/NF-κB signaling pathway. Eur J Pharmacol. 880:1731892020. View Article : Google Scholar : PubMed/NCBI
18	Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G and Bianchi ME: Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 14:431–441. 2007. View Article : Google Scholar : PubMed/NCBI
19	Kim SW, Jin Y, Shin JH, Kim ID, Lee HK, Park S, Han PL and Lee JK: Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol Dis. 46:147–156. 2012. View Article : Google Scholar : PubMed/NCBI
20	Tsoyi K, Lee TY, Lee YS, Kim HJ, Seo HG, Lee JH and Chang KC: Heme-oxygenase-1 induction and carbon monoxide-releasing molecule inhibit lipopolysaccharide (LPS)-induced high-mobility group box 1 release in vitro and improve survival of mice in LPS- and cecal ligation and puncture-induced sepsis model in vivo. Mol Pharmacol. 76:173–182. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kim YM, Kim HJ and Chang KC: Glycyrrhizin reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and endotoxemic mice by p38/Nrf2-dependent induction of HO-1. Int Immunopharmacol. 26:112–118. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wong ML, Xie B, Beatini N, Phu P, Marathe S, Johns A, Gold PW, Hirsch E, Williams KJ, Licinio J and Tabas I: Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: A possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA. 97:8681–8686. 2000. View Article : Google Scholar : PubMed/NCBI
23	Kawase A, Tateishi S and Kazaoka A: Profiling of hepatic metabolizing enzymes and nuclear receptors in rats with adjuvant arthritis by targeted proteomics. Biopharm Drug Dispos. 39:308–314. 2018. View Article : Google Scholar : PubMed/NCBI
24	Kawase A, Kazaoka A, Yamamoto R, Minakata R, Shimada H and Iwaki M: Changes in transporters and metabolizing enzymes in the livers of rats with bile duct ligation. J Pharm Pharm Sci. 22:457–465. 2019. View Article : Google Scholar : PubMed/NCBI
25	Sunman JA, Hawke RL, LeCluyse EL and Kashuba ADM: Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos. 32:359–363. 2004. View Article : Google Scholar : PubMed/NCBI
26	Hartmann G, Kim H and Piquette-Miller M: Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol. 1:189–199. 2001. View Article : Google Scholar : PubMed/NCBI
27	Goralski KB, Hartmann G, Piquette-Miller M and Renton KW: Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol. 139:35–48. 2003. View Article : Google Scholar : PubMed/NCBI
28	Ogiku M, Kono H, Hara M, Tsuchiya M and Fujii H: Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J Pharmacol Exp Ther. 339:93–98. 2011. View Article : Google Scholar : PubMed/NCBI
29	Shi X, Yu L, Zhang Y, Liu Z, Zhang H, Zhang Y, Liu P and Du P: Glycyrrhetinic acid alleviates hepatic inflammation injury in viral hepatitis disease via a HMGB1-TLR4 signaling pathway. Int Immunopharmacol. 84:1065782020. View Article : Google Scholar : PubMed/NCBI
30	Wang Y, Chen Q, Shi C, Jiao F and Gong Z: Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress. Mol Med Rep. 20:4081–4090. 2019.PubMed/NCBI
31	Ketloy C, Engering A, Srichairatanakul U, Limsalakpetch A, Yongvanitchit K, Pichyangkul S and Ruxrungtham K: Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol. 125:18–30. 2008. View Article : Google Scholar : PubMed/NCBI
32	Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, Endres S and Hartmann G: Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 168:4531–4537. 2002. View Article : Google Scholar : PubMed/NCBI
33	Rehli M: Of mice and men: Species variations of toll-like receptor expression. Trends Immunol. 23:375–378. 2002. View Article : Google Scholar : PubMed/NCBI
34	Zhang B, Ramesh G, Uematsu S, Akira S and Reeves WB: TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol. 19:923–932. 2008. View Article : Google Scholar : PubMed/NCBI
35	West AP, Koblansky AA and Ghosh S: Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol. 22:409–437. 2006. View Article : Google Scholar : PubMed/NCBI
36	Rothfuchs AG, Trumstedt C, Wigzell H and Rottenberg ME: Intracellular bacterial infection-induced IFN-gamma is critically but not solely dependent on Toll-like receptor 4-myeloid differentiation factor 88-IFN-alpha beta-STAT1 signaling. J Immunol. 172:6345–6353. 2004. View Article : Google Scholar : PubMed/NCBI
37	Zhang B, Ramesh G, Norbury CC and Reeves WB: Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 72:37–44. 2007. View Article : Google Scholar : PubMed/NCBI
38	Fan HY, Qi D, Yu C, Zhao F, Liu T, Zhang ZK, Yang MY, Zhang LM, Chen DQ and Du Y: Paeonol protects endotoxin-induced acute kidney injury: Potential mechanism of inhibiting TLR4-NF-κB signal pathway. Oncotarget. 7:39497–39510. 2016. View Article : Google Scholar : PubMed/NCBI
39	Hreggvidsdottir HS, Ostberg T, Wähämaa H, Schierbeck H, Aveberger AC, Klevenvall L, Palmblad K, Ottosson L, Andersson U and Harris HE: The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol. 86:655–662. 2009. View Article : Google Scholar : PubMed/NCBI
40	Wähämaa H, Schierbeck H, Hreggvidsdottir HS, Palmblad K, Aveberger AC, Andersson U and Harris HE: High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther. 13:R1362011. View Article : Google Scholar : PubMed/NCBI
41	He ZW, Qin YH, Wang ZW, Chen Y, Shen Q and Dai SM: HMGB1 acts in synergy with lipopolysaccharide in activating rheumatoid synovial fibroblasts via p38 MAPK and NF-κB signaling pathways. Mediators Inflamm. 2013:5967162013. View Article : Google Scholar : PubMed/NCBI